A Review of Autologous Stem Cell Transplantation in Lymphoma

Umar Zahid, Faisal Akbar, Akshay Amaraneni, Muhammad Husnain, Onyee Chan, Irbaz Bin Riaz, Ali McBride, Ahmad Iftikhar, Faiz Anwer

Research output: Research - peer-reviewReview article

Abstract

Purpose of Review: Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients. Recent Findings: There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrated an improved safety profile without compromising the myeloablative efficiency for relapsed or refractory HL. Summary: Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease salvage, and high-dose consolidation or in the maintenance setting.

LanguageEnglish (US)
Pages217-226
Number of pages10
JournalCurrent Hematologic Malignancy Reports
Volume12
Issue number3
DOIs
StatePublished - Jun 1 2017

Fingerprint

Stem Cell Transplantation
Lymphoma
Drug Therapy
Hodgkin Disease
Non-Hodgkin's Lymphoma
Stem Cells
Transplants
Therapeutics
Mantle-Cell Lymphoma
T-Cell Lymphoma
B-Cell Lymphoma
Standard of Care
Maintenance
Safety

Keywords

  • Autologous stem cell transplantation
  • High-dose chemotherapy
  • Lymphoma
  • Novel agents
  • Relapsed/refractory
  • Salvage chemotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Zahid, U., Akbar, F., Amaraneni, A., Husnain, M., Chan, O., Riaz, I. B., ... Anwer, F. (2017). A Review of Autologous Stem Cell Transplantation in Lymphoma. Current Hematologic Malignancy Reports, 12(3), 217-226. DOI: 10.1007/s11899-017-0382-1

A Review of Autologous Stem Cell Transplantation in Lymphoma. / Zahid, Umar; Akbar, Faisal; Amaraneni, Akshay; Husnain, Muhammad; Chan, Onyee; Riaz, Irbaz Bin; McBride, Ali; Iftikhar, Ahmad; Anwer, Faiz.

In: Current Hematologic Malignancy Reports, Vol. 12, No. 3, 01.06.2017, p. 217-226.

Research output: Research - peer-reviewReview article

Zahid, U, Akbar, F, Amaraneni, A, Husnain, M, Chan, O, Riaz, IB, McBride, A, Iftikhar, A & Anwer, F 2017, 'A Review of Autologous Stem Cell Transplantation in Lymphoma' Current Hematologic Malignancy Reports, vol 12, no. 3, pp. 217-226. DOI: 10.1007/s11899-017-0382-1
Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Riaz IB et al. A Review of Autologous Stem Cell Transplantation in Lymphoma. Current Hematologic Malignancy Reports. 2017 Jun 1;12(3):217-226. Available from, DOI: 10.1007/s11899-017-0382-1
Zahid, Umar ; Akbar, Faisal ; Amaraneni, Akshay ; Husnain, Muhammad ; Chan, Onyee ; Riaz, Irbaz Bin ; McBride, Ali ; Iftikhar, Ahmad ; Anwer, Faiz. / A Review of Autologous Stem Cell Transplantation in Lymphoma. In: Current Hematologic Malignancy Reports. 2017 ; Vol. 12, No. 3. pp. 217-226
@article{425229b09cab4bfaa2f49e9e3c920ec4,
title = "A Review of Autologous Stem Cell Transplantation in Lymphoma",
abstract = "Purpose of Review: Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients. Recent Findings: There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrated an improved safety profile without compromising the myeloablative efficiency for relapsed or refractory HL. Summary: Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease salvage, and high-dose consolidation or in the maintenance setting.",
keywords = "Autologous stem cell transplantation, High-dose chemotherapy, Lymphoma, Novel agents, Relapsed/refractory, Salvage chemotherapy",
author = "Umar Zahid and Faisal Akbar and Akshay Amaraneni and Muhammad Husnain and Onyee Chan and Riaz, {Irbaz Bin} and Ali McBride and Ahmad Iftikhar and Faiz Anwer",
year = "2017",
month = "6",
doi = "10.1007/s11899-017-0382-1",
volume = "12",
pages = "217--226",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - A Review of Autologous Stem Cell Transplantation in Lymphoma

AU - Zahid,Umar

AU - Akbar,Faisal

AU - Amaraneni,Akshay

AU - Husnain,Muhammad

AU - Chan,Onyee

AU - Riaz,Irbaz Bin

AU - McBride,Ali

AU - Iftikhar,Ahmad

AU - Anwer,Faiz

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Purpose of Review: Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients. Recent Findings: There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrated an improved safety profile without compromising the myeloablative efficiency for relapsed or refractory HL. Summary: Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease salvage, and high-dose consolidation or in the maintenance setting.

AB - Purpose of Review: Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients. Recent Findings: There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrated an improved safety profile without compromising the myeloablative efficiency for relapsed or refractory HL. Summary: Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease salvage, and high-dose consolidation or in the maintenance setting.

KW - Autologous stem cell transplantation

KW - High-dose chemotherapy

KW - Lymphoma

KW - Novel agents

KW - Relapsed/refractory

KW - Salvage chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85018762197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018762197&partnerID=8YFLogxK

U2 - 10.1007/s11899-017-0382-1

DO - 10.1007/s11899-017-0382-1

M3 - Review article

VL - 12

SP - 217

EP - 226

JO - Current Hematologic Malignancy Reports

T2 - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 3

ER -